Telomir Pharmaceuticals’ (NASDAQ:TELO – Get Free Report) lock-up period is set to end on Wednesday, August 7th. Telomir Pharmaceuticals had issued 1,000,000 shares in its initial public offering on February 9th. The total size of the offering was $7,000,000 based on an initial share price of $7.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.
Telomir Pharmaceuticals Trading Down 3.6 %
TELO stock opened at $3.34 on Friday. Telomir Pharmaceuticals has a 12-month low of $3.11 and a 12-month high of $20.72. The firm has a fifty day moving average price of $4.69.
Telomir Pharmaceuticals (NASDAQ:TELO – Get Free Report) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.23) earnings per share for the quarter.
Institutional Investors Weigh In On Telomir Pharmaceuticals
Telomir Pharmaceuticals Company Profile
Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.
Read More
- Five stocks we like better than Telomir Pharmaceuticals
- Stock Average Calculator
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- How to Find Undervalued Stocks
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
- Energy and Oil Stocks Explained
- Intel Loses a Quarter of Its Value After Horrible Earnings Report
Receive News & Ratings for Telomir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telomir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.